Assignment of DPA to a family member or guardian should be offered to all patients 18 years of age or older
Patients with a history of venous or arterial thrombosis personally before the age of 40 years unless associated with a central line
Patients must be post-menopausal; post-menopausal will be defined as women meeting any of the following criteria:* >= 60 years of age; or* < 60 years of age and amenorrheic for >= 12 months prior to day 1 if uterus/ovaries are intact; or* < 60 years of age, and the last menstrual period 6-12 months prior to day 1, if intact uterus/ovaries and meets biochemical criteria for menopause (follicle-stimulating hormone [FSH] and estradiol within institutional standard for postmenopausal status); or* < 60 years of age, without a uterus, and meets biochemical criteria for menopause (FSH and estradiol within institutional standards for postmenopausal status); or* < 60 years of age and history of bilateral oophorectomy; surgery must have been completed at least 4 weeks prior to day 1; or* Prior radiation castration with amenorrhea for at least 6 months
Signed informed consent by subject (age >= 18 years) or by parent/guardian (subject age < 18 years); information will be provided to potential subjects and their parents/guardians (as appropriate) by oral discussion with opportunity for question and answer and the written informed consent document; subjects less than 18 years of age capable of giving assent will be included in these discussions and will be asked for written assent on the same document as the parents/guardians give consent; if feasible, both parents (or guardians) will be included in these discussions and will be asked to sign the written consent document; if a second parent or guardian is unavailable, this will be explained in writing on the written consent document; if subjects age 18 years or older are unable to provide informed consent, then they will not be enrolled in this study
Age > 18 years
PHASE I: >= 3 years and =< 18 years of age at the time of study enrollment, if able to swallow whole capsules
40 to 75 years of age with diabetes per American College of Cardiology (ACC)/American Heart Association (AHA) ACC/AHA 2013 guidelines
Patients must be:* < 12 months (< 365 days) of age at diagnosis with INRG stage L1; or* < 18 months (< 547 days) of age at diagnosis with INRG stage L2 or stage Ms neuroblastoma/ganglioneuroblastoma
Group C: patients < 18 months (< 547 days) of age with newly diagnosed INRG stage Ms neuroblastoma/ganglioneuroblastoma
Age >= 18 years
Age:* Phase 1 (Part A)** Patients must be > than 12 months and =< 21 years of age at the time of study enrollment* Phase 2 (Part B and Part C)** Patients must be > than 12 months and =< 30 years of age at the time of study enrollment
Parts A & C: patients must be >= 12 months and < 18 years of age at the time of study enrollment
Part B7: patients must be >= 12 months and < 18 years of age at the time of study enrollment
Age >= 14 years (>= 18 years in Germany)
Patients with body mass index (BMI) < 3rd percentile for age, as defined by WHO criteria for patients 1-2 years of age and Centers for Disease Control and Prevention (CDC) criteria for patients > 2 years of age, are not eligible
Female patients must have a bone age of equal to or greater than 12 years of age as determined by local read of appropriate radiographic imaging
Male patients must have a bone age of equal to or greater than 14 years of age as determined by local read of appropriate radiographic imaging
Cohort 1 patients must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1* Note: patients in Cohort 1 will be stratified as follows:** Stratum 1: Patients >= 11 years of age but < 18 years** Stratum 2: Patients >= 11 years of age but < 50 years
Efficacy Phase: Patients must be =< 40 years of age at the time of enrollment
Patient must have had a cancer diagnosis < 22 years of age, irrespective of current age
Patients must be >= 18 years of age
Age >= 6 years at the NCI clinical center (>= 18 years at other participating sites)
Standard risk 1: Patient must be < 11 years of age at enrollment
Standard risk 2: Patients must be >= 11 and < 25 years of age at enrollment